New cancer drug LBL-033 tested in 26 patients – early results promising?
NCT ID NCT05779163
First seen May 17, 2026 · Last updated May 17, 2026
Summary
This early-phase trial tested a new drug called LBL-033 in 26 adults with advanced solid tumors that had not responded to other treatments. The main goals were to check safety, find the best dose, and see if the drug could shrink or control the cancer. The study is now complete, and results will help guide future research.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fujian Cancer Hospital
Fuzhou, Fujian, 350014, China
-
Henan Cancer Hospital
Zhengzhou, Henan, 450003, China
-
Liaoning Cancer Hospital & Institute
Shenyang, Liaoning, 110801, China
-
Obstetrics & Gynecology Hospital of Fudan University
Shanghai, Shanghai Municipality, 200011, China
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510062, China
-
West China Second University Hospital,Sichuan University
Chengdu, Sichuan, 610044, China
Conditions
Explore the condition pages connected to this study.